[HTML][HTML] The present and future of measurable residual disease testing in acute myeloid leukemia
Considerable progress has been made in the past several years in the scientific
understanding of, and available treatments for, acute myeloid leukemia (AML). Achievement …
understanding of, and available treatments for, acute myeloid leukemia (AML). Achievement …
Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia
LW Dillon, J Higgins, H Nasif, M Othus, L Beppu… - medRxiv, 2023 - pmc.ncbi.nlm.nih.gov
The presence of measurable residual disease (MRD) is strongly associated with treatment
outcomes in acute myeloid leukemia (AML). Despite the correlation with clinical outcomes …
outcomes in acute myeloid leukemia (AML). Despite the correlation with clinical outcomes …
Real-world experience of measurable residual disease response and prognosis in acute myeloid leukemia treated with venetoclax and azacitidine
SY Ong, M Tan Si Yun, NA Abdul Halim, D Christopher… - Cancers, 2022 - mdpi.com
Simple Summary More than 90% of patients with acute myeloid leukemia carry aberrant
markers that can be detected using flow cytometry. Monitoring low levels of residual disease …
markers that can be detected using flow cytometry. Monitoring low levels of residual disease …
Fludarabine melphalan reduced intensity conditioning vs radiation-based myeloablative conditioning in patients undergoing allogeneic transplantation for acute …
A Blackmon, M Afkhami, D Yang, S Mokhtari… - Bone Marrow …, 2024 - nature.com
Patients with AML and measurable residual disease (MRD) undergoing allogeneic
hematopoietic cell transplantation (HCT) may benefit from myeloablative conditioning (MAC) …
hematopoietic cell transplantation (HCT) may benefit from myeloablative conditioning (MAC) …
[PDF][PDF] Monitoring Measurable Residual Disease in ALL and AML
P Bader, H Kreyenberg, G Ossenkoppele… - The EBMT Handbook …, 2024 - library.oapen.org
In ALL evaluation of molecular treatment response, assessment of minimal residual disease,
nowadays named measurable residual disease (MRD), is a substantial independent …
nowadays named measurable residual disease (MRD), is a substantial independent …
[PDF][PDF] MRD Monitoring by Multiparametric Flow Cytometry in AML: Is It time to Incorporate Immune Parameters? Cancers 2022, 14, 4294
I Pessach, T Spyropoulos, E Lamprianidou… - 2022 - academia.edu
Acute myeloid leukemia (AML) is a heterogeneous group of clonal myeloid disorders
characterized by intrinsic molecular variability. Pretreatment cytogenetic and mutational …
characterized by intrinsic molecular variability. Pretreatment cytogenetic and mutational …
[引用][C] A Review from Research Tool to Clinical Diagnostic
C Kazanecki, A Seyda, N Martin, DL de Menezes - Journal of Precision Medicine …, 2022